-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at HC Wainwright
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Get Rating) in a report published on Friday morning. They currently have a $37.00 target price on the stock. HC Wainwright also issued estimates for Biomea Fusion's FY2024 earnings at ($2.53) EPS, FY2025 earnings at ($2.68) EPS and FY2026 earnings at ($2.28) EPS.
Separately, EF Hutton Acquisition Co. I reduced their target price on Biomea Fusion from $27.00 to $22.00 and set a buy rating on the stock in a research report on Tuesday, November 8th.
Get Biomea Fusion alerts:Biomea Fusion Price Performance
Shares of NASDAQ:BMEA opened at $7.91 on Friday. The business's 50-day moving average is $8.41 and its 200 day moving average is $10.01. Biomea Fusion has a 1 year low of $2.84 and a 1 year high of $14.20. The firm has a market capitalization of $232.52 million, a P/E ratio of -3.24 and a beta of -1.80.
Insider Buying and Selling at Biomea Fusion
In related news, Director Michael J.M. Hitchcock bought 5,000 shares of the stock in a transaction dated Monday, November 14th. The shares were purchased at an average price of $7.93 per share, for a total transaction of $39,650.00. Following the completion of the purchase, the director now directly owns 5,000 shares of the company's stock, valued at $39,650. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 45.70% of the company's stock.Institutional Investors Weigh In On Biomea Fusion
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Biomea Fusion by 2.0% during the first quarter. BlackRock Inc. now owns 1,705,442 shares of the company's stock worth $7,606,000 after buying an additional 32,634 shares during the period. Vanguard Group Inc. boosted its holdings in Biomea Fusion by 18.5% in the third quarter. Vanguard Group Inc. now owns 803,118 shares of the company's stock valued at $7,854,000 after purchasing an additional 125,311 shares during the period. Laurion Capital Management LP boosted its holdings in Biomea Fusion by 2.2% in the third quarter. Laurion Capital Management LP now owns 429,400 shares of the company's stock valued at $4,200,000 after purchasing an additional 9,251 shares during the period. Citadel Advisors LLC boosted its holdings in Biomea Fusion by 540.5% in the second quarter. Citadel Advisors LLC now owns 335,191 shares of the company's stock valued at $4,016,000 after purchasing an additional 282,855 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Biomea Fusion by 1,475.9% in the second quarter. JPMorgan Chase & Co. now owns 273,925 shares of the company's stock valued at $3,281,000 after purchasing an additional 256,543 shares during the period. Institutional investors and hedge funds own 58.19% of the company's stock.
Biomea Fusion Company Profile
(Get Rating)
Biomea Fusion, Inc, a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
Further Reading
- Get a free copy of the StockNews.com research report on Biomea Fusion (BMEA)
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- Four Profitable RV Stocks To Ride Out Recession
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
HC Wainwright reaffirmed their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Get Rating) in a report published on Friday morning. They currently have a $37.00 target price on the stock. HC Wainwright also issued estimates for Biomea Fusion's FY2024 earnings at ($2.53) EPS, FY2025 earnings at ($2.68) EPS and FY2026 earnings at ($2.28) EPS.
HC Wainwright在週五上午發佈的一份報告中重申了他們對Biomea Fusion(納斯達克：BMEA-GET評級)股票的買入評級。他們目前對該股的目標價為37.00美元。HC Wainwright還發布了對Biomea Fusion 2024財年每股收益(2.53美元)、2025財年每股收益(2.68美元)和2026財年每股收益(2.28美元)的預期。
Separately, EF Hutton Acquisition Co. I reduced their target price on Biomea Fusion from $27.00 to $22.00 and set a buy rating on the stock in a research report on Tuesday, November 8th.
另外，EF Hutton Acquisition Co.I在11月8日週二的一份研究報告中將Biomea Fusion的目標價從27.00美元下調至22.00美元，並對該股設定了買入評級。
Biomea Fusion Price Performance
Biomea融合性價比
Shares of NASDAQ:BMEA opened at $7.91 on Friday. The business's 50-day moving average is $8.41 and its 200 day moving average is $10.01. Biomea Fusion has a 1 year low of $2.84 and a 1 year high of $14.20. The firm has a market capitalization of $232.52 million, a P/E ratio of -3.24 and a beta of -1.80.
納斯達克：非洲、中東和非洲股票上週五開盤報7.91美元。該業務的50日移動均線切入位在8.41美元，200日移動均線切入位在10.01美元。Biomea Fusion的一年低點為2.84美元，一年高位為14.20美元。該公司的市值為2.3252億美元，本益比為-3.24，貝塔係數為-1.80。
Insider Buying and Selling at Biomea Fusion
Biomea Fusion的內部買入和賣出
Institutional Investors Weigh In On Biomea Fusion
機構投資者參與Biomea Fusion
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Biomea Fusion by 2.0% during the first quarter. BlackRock Inc. now owns 1,705,442 shares of the company's stock worth $7,606,000 after buying an additional 32,634 shares during the period. Vanguard Group Inc. boosted its holdings in Biomea Fusion by 18.5% in the third quarter. Vanguard Group Inc. now owns 803,118 shares of the company's stock valued at $7,854,000 after purchasing an additional 125,311 shares during the period. Laurion Capital Management LP boosted its holdings in Biomea Fusion by 2.2% in the third quarter. Laurion Capital Management LP now owns 429,400 shares of the company's stock valued at $4,200,000 after purchasing an additional 9,251 shares during the period. Citadel Advisors LLC boosted its holdings in Biomea Fusion by 540.5% in the second quarter. Citadel Advisors LLC now owns 335,191 shares of the company's stock valued at $4,016,000 after purchasing an additional 282,855 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Biomea Fusion by 1,475.9% in the second quarter. JPMorgan Chase & Co. now owns 273,925 shares of the company's stock valued at $3,281,000 after purchasing an additional 256,543 shares during the period. Institutional investors and hedge funds own 58.19% of the company's stock.
對沖基金和其他機構投資者最近改變了他們在該股的頭寸。貝萊德股份有限公司在第一季度將其在Biomea Fusion的股票持倉量增加了2.0%。貝萊德股份有限公司在此期間增持了32,634股，目前持有1,705,442股該公司股票，價值7,606,000美元。先鋒集團(Vanguard Group Inc.)在第三季度增持了Biomea Fusion 18.5%的股份。先鋒集團目前持有803,118股該公司股票，價值7,854,000美元，在此期間又購買了125,311股。Laurion Capital Management LP在第三季度增持了2.2%的Biomea Fusion。Laurion Capital Management LP現在擁有該公司429,400股股票，價值4,200,000美元，在此期間又購買了9,251股。Citadel Advisors LLC在第二季度將其在Biomea Fusion的持股增加了540.5%。Citadel Advisors LLC在此期間額外購買了282,855股，目前擁有335,191股該公司股票，價值4,016,000美元。最後，摩根大通在第二季度將其在Biomea Fusion的持股增加了1,475.9%。摩根大通在此期間增持了256,543股，目前持有273,925股該公司股票，價值3,281,000美元。機構投資者和對沖基金持有該公司58.19%的股票。
Biomea Fusion Company Profile
Biomea Fusion公司簡介
(Get Rating)
(獲取評級)
Biomea Fusion, Inc, a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
Biomea Fusion，Inc.是一家生物製藥公司，專注於發現和開發共價小分子藥物，用於治療基因定義的癌症和代謝性疾病患者。它的主要候選產品是BMF-219，一種口服生物可用、有效和選擇性的薄荷素共價抑制劑，它是多種癌症致癌信號中的轉錄調節因數。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Biomea Fusion (BMEA)
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- Four Profitable RV Stocks To Ride Out Recession
- 免費獲取StockNews.com關於Biomea Fusion(BMEA)的研究報告
- 2023年值得關注的5個下跌但不是下跌的股票
- Chewy能否在2023年獲得兩位數的增長？
- 禮來公司預計將實現持久增長，儘管面臨眼前的挑戰
- Madrigal製藥公司的股票在一天內上漲了200%，原因如下
- 四隻盈利的房車股安然度過經濟衰退
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
接受Biomea Fusion Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Biomea Fusion和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧